2 assets in Sex Cord-Stromal Tumor

Therapeutic assets addressing Sex Cord-Stromal Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Sex Cord-Stromal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Sex Cord-Stromal Tumor	National Cancer Institute (NCI)	P2	CCC (53)